Evecxia Therapeutics Receives Notice of Allowance from the US PTO Covering EVX‑101
Shots:
- The US patent (17/877,699) covers the composition, specific physical characteristics, excipients, 5-HTP, and carbidopa doses, in vitro dissolution profiles, and human in vivo PK profiles of EVX-101
- In the P-I study, it demonstrated the ability to provide sustained and adequate 5-HTP exposure while ensuring safety and tolerability
- EVX-101 is a novel, proprietary gastro-retentive, sustained-release tablet formulation of 5-HTP, bilayers (swelling layer, and modified release layer), the natural precursor to serotonin, and low-dose carbidopa being developed for adjunctive therapy in major depressive disorder patients responding inadequately to a first-line serotonin reuptake inhibitor
Ref: Businesswire | Image: Evecxia Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
